Apellis Pharmaceuticals (APLS, $38.88) was a top loser over the last three months, falling -2 to $38.88 per share. A.I.dvisor analyzed 873 stocks in the Biotechnology Industry for the 3-month period ending July 25, 2024, and found that of them (6) exhibited an Uptrend while of them (3) demonstrated a Downtrend.